Colorectal Cancer turns everything upside down
This March, Fujifilm is proud to join the global cancer care community to mark Colorectal Cancer Awareness Month. Did you know that CRC diagnoses are increasingly seen in younger people? A study published by BMJ Journals showed an increase in CRC incidence in adults aged 20–49 years in Europe. The largest increase in CRC incidence occurred among people aged 20–39 years, with incidence of colon cancer increasing by 6.4%-9.3% annually. This is a global trend, and this is why organization's such as the American Cancer Society is recommending lowering the CRC screening age from 50 to 45 years old.1
Despite the considerable progress we’ve made in fighting CRC, far too many cases are detected at later stages when treatment options available to people are limited.2 Early screening and diagnosis are the most effective tools in reducing death rates, yet millions still face barriers related to awareness, access, and diagnostic.3
Fujifilm is at the forefront of tackling these challenges. Our imaging technologies and state-of-the-art AI-powered diagnostic tools empower clinicians to detect CRC earlier, improve workflow efficiency, and enhance outcomes. Through constant innovation, collaboration, and a commitment to closing and addressing inequity in access, we are driving meaningful change in CRC care, supporting clinicians to deliver the best possible care to their community.
Elsewhere, across our Life Sciences porfolio, the manufacture of cell culture media and reagents support cutting-edge cancer R&D.
Advancing colorectal cancer detection with innovation
Fujifilm is transforming colorectal cancer (CRC) detection with state-of-the-art AI-assisted imaging and diagnostic technologies. By equipping clinicians with innovative tools, we enhance polyp detection rates, improve diagnostic confidence, and streamline clinical workflows. Our AI-driven diagnostics help reduce variability and improve clinician accuracy in identifying lesions, setting new standards in diagnostic excellence based on over 40 years of expertise in endoscopy.4
Fujifilm’s AI-powered imaging solution, CAD-EYE, enhances polyp detection in real-time, improving diagnostic confidence. Advanced visualisation techniques such as Linked Color Imaging and Blue Light Imaging allow for earlier and more precise identification of abnormalities.5 Our innovative tools empower healthcare professionals to make faster and more accurate decisions.
Within our life sciences portfolio we provide the innovations that enable scientists to grow and study cancer cells, investigate the mechanisms of tumour development, test potential therapeutic drugs, or analyse the effects of different factors on cancer cell behaviour; providing the potential to bring new and critical treatments for CRC closer to people living with cancer.
Breaking barriers to early screening
Colorectal cancer is highly treatable when caught early, yet many people delay or avoid screening due to stigma, fear, or lack of awareness. Fujifilm is committed to tackling these challenges by educating communities and healthcare professionals on the importance of early detection and supporting healthcare systems with innovative, cost-effective diagnostic solutions. Our portable imaging technology is bringing high-quality diagnostics to underserved and remote communities, ensuring that geography and socioeconomic status do not limit access to life-saving screenings.
Our NURA health screening centers in emerging countries, designed to expand access to life-saving cancer screenings in underserved communities, are driving earlier detection of cancers and helping reduce health inequities globally. Fujifilm aims to expand the number of NURA health screening centers to 100 locations by the fiscal year 2030.6 Through collaborations with healthcare professionals and advocacy organizations, we are raising awareness of colorectal cancer and improving early detection rates worldwide.
A Visionary Partner for World Cancer Day
Fujifilm is proud to be a Visionary Partner to World Cancer Day 2025-2027, a global initiative led by the Union for International Cancer Control (UICC), in 2024 and will continue the partnership as a “Visionary Partner” from 2025 to 2027. At the heart of our partnership with UICC for 2025 is the celebration of personal stories from individuals affected by cancer. United by unique stories of resilience and hope, we support communities, caregivers, and healthcare professionals while advancing our mission to make cancer prevention, detection, and treatment accessible to all. Fujifilm and the UICC are committed to reducing the global cancer burden and improving patient outcomes through collaboration and innovation.
United against colorectal cancer
1 https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html
2 https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
3 https://cancer-inequalities.jrc.ec.europa.eu/sites/default/files/ECIR-inequalities-factsheet-colorectal-cancer-screening-Mar2024.pdf
4 https://healthcaresolutions-us.fujifilm.com/blog/endoscopy/innovating-with-ai-to-advance-colonoscopy/
5 https://seelearn-emea.fujifilm.com/endoscopy/technologies/cad-eye/
6 https://www.fujifilm.com/de/en/about/brand/story/worldcancerday